This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on August 26, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use-Induced Respiratory Depression — In Vivo Validation

Closed

75F40126Q00382Federal

Submission Closed09/10/2026, 07:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Federal

RFI Lupus Research Program (LRP) Public

Solicitation # HT9427RFI2027LRP

The Defense Health Agency, through the Congressionally Directed Medical Research Programs, has issued a Request for Information regarding the Lupus Research Program for fiscal year 2027. This action is strictly for information and planning purposes to identify future research focus areas and funding opportunities; it is not a solicitation, and no contracts will be awarded based on this announcement. The program aims to cure lupus by funding research to improve diagnosis, prevention, and treatment, with a specific focus on understanding biological or genetic patient subsets, disease mechanisms, and enhancing overall patient quality of life. Interested parties from academia, industry, non-profit organizations, and the public are invited to provide feedback on critical research gaps and underfunded areas. Responses must be submitted via Survey Monkey by November 16, 2026. While historical appropriations from fiscal years 2017 through 2024 and 2026 totaled 75 million dollars, funds for fiscal year 2027 have not yet been appropriated. Respondents are cautioned not to submit proprietary or sensitive information through the survey portal, as the government cannot protect such data, and all costs associated with responding to this request are the responsibility of the participant.

Defense Health Agency

POSTED

DEADLINE

Preclinical & Translational Research SupportThis subcontract for Preclinical and Translational Research Support involves providing specialized laboratory services and preclinical testing to prime contractors working on Defense Health Agency lupus research projects. The scope of work focuses on supporting the transition from laboratory research to clinical application through the development of animal models, in-vitro and in-vivo modeling, and preclinical toxicity testing. The primary deliverables include validated models and comprehensive preclinical test results. The project is managed under the Department of Defense for the Defense Health Agency and is categorized under NAICS code 541714. Performance of the contract will take place in Frederick, Maryland. Interested parties should note the response deadline of November 16, 2026.

Defense Health Agency

POSTED

DEADLINE

Patient Quality of Life (QoL) Clinical StudiesThis subcontract focuses on conducting patient-centric clinical research for the Defense Health Agency to evaluate factors affecting the quality of life for lupus patients. The scope of work includes comprehensive clinical trial management, the design of patient surveys, psychosocial assessments, and detailed health outcomes research. The primary objective is to generate and deliver clinical study reports and outcome data to prime contractors. The project is categorized under NAICS code 541714 and will be performed in Frederick, Maryland. Interested parties should note that the response deadline is November 16, 2026, following a posting date of October 14, 2026.

Defense Health Agency

POSTED

DEADLINE

Disease Mechanism & Intervention ResearchThis subcontract opportunity involves conducting specialized research into lupus disease mechanisms and analyzing patient responses to medical interventions to support prime contractors on Defense Health Agency projects. The scope of work focuses on translational research, pharmacological studies, and the mapping of disease pathways to deliver critical analysis of intervention response data. The project is associated with NAICS code 541714 and will be performed in Frederick, Maryland. Interested parties should note that the solicitation was posted on October 14, 2026, with a response deadline set for November 16, 2026.

Defense Health Agency

POSTED

DEADLINE

Lupus Genetic & Biological Subset ResearchThe Lupus Genetic and Biological Subset Research subcontract involves providing specialized biological and genetic analysis to support prime contractors on Defense Health Agency research projects. The scope of work focuses on identifying and categorizing lupus patient subsets to enable targeted treatment through genomic sequencing, biomarker identification, biological assay development, and detailed patient cohort analysis. The primary deliverable for this effort is the provision of categorized biological and genetic data sets. This project is managed under the Department of Defense for the Defense Health Agency, with performance taking place in Frederick, Maryland. The opportunity was posted on October 14, 2026, with a response deadline of November 16, 2026. The work is classified under NAICS code 541714, reflecting its focus on research and development in the biotechnology field.

Defense Health Agency

POSTED

DEADLINE

Experimental Functional Discovery and Validation ServicesThe Experimental Functional Discovery and Validation Services subcontract, issued by the National Science Foundation under Tip - Core Programs, focuses on the laboratory testing and experimental validation of designed proteins and cells. The selected provider will support prime contractors on NSF X-Labs bioengineering projects by executing critical technical tasks, including bio-assays, functional screening, stability analysis, and metabolic requirement testing. These operations will utilize analytical chemistry tools and high-throughput screening equipment to ensure precise results. The primary deliverables for this engagement are quantitative performance data and detailed experimental validation reports. Interested parties should note that the response deadline is February 8, 2027, and the work falls under NAICS code 541714. This effort is central to the bioengineering objectives of the NSF X-Labs initiative, ensuring that designed biological components meet specific functional requirements.

POSTED

DEADLINE

Protein Design and Synthesis ServicesThis subcontract for Protein Design and Synthesis Services supports prime contractors on National Science Foundation X-Labs bioengineering projects. The scope of work involves the computational design and physical synthesis of novel proteins, including peptide synthesis, sequence optimization, and the development of synthetic proteins with specific molecular behaviors. The successful provider must possess expertise in protein folding and utilize high-throughput protein synthesis platforms to deliver synthesized protein samples along with comprehensive sequence and structure data. Managed by the National Science Foundation under the Tip - Core Programs, this opportunity is categorized under NAICS code 541714. The solicitation was posted on October 14, 2026, with a response deadline set for February 8, 2027.

POSTED

DEADLINE

Surgical Validation and Clinical Testing ServicesThe Surgical Validation and Clinical Testing Services subcontract supports prime contractors on projects for the Defense Advanced Research Projects Agency Biological Technologies Office. The scope of work focuses on providing medical validation services, which include designing test cases for Component Gates utilizing synthetic tissue models, cadaveric models, and surgical simulation labs. The contractor is responsible for managing clinical trial protocols and obtaining necessary IRB approvals to validate outcomes related to surgical independence. Final deliverables consist of comprehensive validation reports and certifications of clinical efficacy. This opportunity is categorized under NAICS code 541714 and was posted on October 14, 2026, with a response deadline of November 2, 2026.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

DARPA Surgical Competition (DSC) Second Industry Day

Solicitation # DARPA-SN-27-02

The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is hosting a Second Industry Day for the DARPA Surgical Competition (DSC) under solicitation number DARPA-SN-27-02. This virtual event is scheduled for November 4, 2026, from 4:00 PM to 6:00 PM Eastern Time, with a registration deadline of November 2, 2026. While this notice is not a formal solicitation for proposals, it serves to engage potential competitors in a competition aimed at establishing the state of the art for open, robotic trauma surgery and developing a minimum viable product for scalable, autonomous robotic surgical assistance. The competition will evaluate platforms across three primary performance lanes: Component Gates, which assess system safety and autonomy through medical knowledge, physical capability, and rapid learning; Surgical Collaboration, which tests the ability to work alongside a human surgeon; and Surgical Independence, which evaluates the platform's ability to independently plan and execute end-to-end trauma procedures. The DSC will be conducted at the unclassified level. Technical and administrative inquiries are directed to Program Manager Jeremy Pamplin at SurgicalCompetition@darpa.mil.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

NSF X-Labs Initiative - From Sequence to Function

Solicitation # NSF-Topic4-FY26-XLabsSequence-to-Function

The National Science Foundation Directorate for Technology, Innovation and Partnerships is soliciting written proposals for the NSF X-Labs initiative, specifically focusing on the bioengineering technical domain from sequence to function. This opportunity is issued under the Other Transactions Agreement Solutions Offering and utilizes Other Transaction contracts pursuant to 42 U.S.C 19116, meaning it is neither a FAR-based procurement nor a financial assistance instrument. The program is structured in phases, beginning with Phase 0, which lasts approximately 9 to 12 months starting in September 2027, followed by a potential Phase 1 lasting 24 to 36 months starting in June 2028. All work must be performed within the United States. The selection process is a two-step competitive evaluation consisting of a written proposal and a subsequent oral presentation for selected teams. Proposals are evaluated based on team qualifications, structure, mission clarity, and outcomes. Lead organizations must be registered in the System for Award Management and provide a Unique Entity Identifier. Due to the nature of the bioengineering domain, teams must provide specific plans for biosafety and biosecurity, including assessments of dangerous gain-of-function. Awards are milestone-based, with payments scheduled quarterly upon the successful completion of documented technical exit criteria. Organizational Conflicts of Interest are managed using FAR Subpart 9.5 as a framework, requiring full disclosure of any potential conflicts to the Agreements Officer Representative. Written proposals must be submitted as PDFs via the NSF submission portal by February 8, 2027.

POSTED

DEADLINE

Clinical Trial Execution and ManagementThis subcontract for Clinical Trial Execution and Management supports prime contractors on NIH Collaborative Program Grant projects under the Department of Health and Human Services. The scope of work involves the operational execution of clinical trials, specifically focusing on managing participant enrollment, conducting follow-up assessments, and utilizing clinical facilities and Electronic Medical Records to maintain strict study timelines. The contractor is responsible for delivering enrolled patient cohorts, comprehensive clinical data sets, and trial performance reports. Strict adherence to regulatory standards is required, including compliance with 45 CFR Part 46, obtaining necessary IRB approvals, and ensuring proper registration with ClinicalTrials.gov. The project falls under NAICS code 541714 and has a response deadline of September 26, 2029.

National Institutes Of Health

POSTED

DEADLINE

Clinical Trial Site/CRO ServicesThis subcontract for Clinical Trial Site/CRO Services supports prime contractors on NIH P01 clinical trials by managing participant recruitment, enrollment, and clinical data collection. The scope of work includes overseeing site activation and the implementation of electronic tracking systems, utilizing specialized tools such as CTMS, EDC software, and patient registries. To ensure regulatory compliance, the provider must maintain GCP certification and adhere to 45 CFR Part 46 and ClinicalTrials.gov registration requirements. The project is managed under the National Institutes of Health within the Department of Health and Human Services, falling under NAICS code 541714. A key deliverable of the contract is the provision of standardized activation and enrollment performance data required for the Research Performance Progress Report. The solicitation was posted on October 14, 2026, with a response deadline set for May 25, 2029.

National Institutes Of Health

POSTED

3 days ago

DEADLINE

in over 2 years

AI Contract Overview

The U.S. Food and Drug Administration is issuing a sole source, firm-fixed-price contract to Charles River Laboratories for a twelve month preclinical study. The research aims to evaluate the efficacy of naloxone and alternative reversal agents in treating respiratory depression caused by polysubstance use, specifically addressing the prevalence of fentanyl adulterated with xylazine, d-methamphetamine, or alprazolam. The study will utilize male CD rats to simultaneously measure respiratory and cardiovascular changes, as these systems are closely linked during drug-induced respiratory failure. The project consists of a four-phase in vivo study involving surgically instrumented animals. Key tasks include using whole body plethysmography for respiratory monitoring and implanted telemetry for continuous cardiovascular data collection. The contractor is responsible for collecting blood samples at five prespecified time points for pharmacokinetic analysis to be performed by the FDA. All work will be conducted in an AAALAC-accredited facility under non-GLP conditions, with statistical analysis performed via ANOVA.

General Info

FDA sole source contract for Charles River Laboratories to study naloxone reversal efficacy.

Agency

Department Of Health And Human Services → FDA Office Of Acq Grant Svcs

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

MD, USA

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed

PostedAug 26

Presolicitation

Response DeadlineSep 10

Deadline has passed

Submission Closed

09/10/2026, 07:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → FDA Office Of Acq Grant Svcs

Contacts2 people available

OfficeRockville, MD, 20852, USA

Organization / AgencyDepartment Of Health And Human Services → FDA Office Of Acq Grant Svcs

Office AddressRockville, MD, 20852, USA

Contacts

Kimberly Pennix

Ian Weiss

Full Description

Title: Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use-Induced Respiratory Depression — In Vivo Validation

Agency: U.S. Food and Drug Administration (FDA) Notice Type: Presolicitation: Firm-Fixed Price

DEA surveillance data show that street fentanyl is frequently adulterated with xylazine, d-methamphetamine, or alprazolam — each of which induces respiratory depression through a distinct mechanism. Approximately 80% of opioid overdose cases involve multiple drugs, yet naloxone — the primary FDA-approved reversal agent — was developed and tested for opioid-only scenarios. This mechanistic complexity creates uncertainty about naloxone's efficacy in polysubstance overdose and raises the question of what alternative or adjunct therapies may be needed.

Drug-induced respiratory changes are closely linked to cardiovascular (CV) changes. When a drug disrupts respiration, the heart alters its function to compensate for failing oxygen delivery; however, the same drugs may also impair CV function, reducing that compensatory drive. Simultaneous measurement of both systems is therefore essential.

The U.S. Food and Drug Administration (FDA) intends to solicit a period of performance of (12) months from the date of award. Study initiation is anticipated within two (2) months of award, subject to research animal availability., sole source (in accordance with FAR 6.103-1), firm-fixed-price purchase order from Charles River Laboratories (CRL) 54943 N Main St, Mattawan, MI 49071. The North American Industry Classification System (NAICS) code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology), anticipated period of performance consists of a 1-year base purchase order.

This notice is not a request for competitive proposals.

Objectives:

This purchase order directs contractor to conduct a 4-phase in vivo study in male rats to accomplish the following:

Simultaneously measure drug-induced changes in respiratory and cardiovascular parameters.
Evaluate the ability of naloxone and alternative reversal agents to restore respiratory and CV function following polysubstance-induced full respiratory depression.
Collect blood samples at five (5) prespecified time points per animal for pharmacokinetic (PK) analysis to be conducted at the FDA.

Scope:

Contractor shall conduct four (4) sequential study phases in male CD rats. Each phase uses a parallel group design with n=4 animals per treatment group. All drug combinations shall be administered via intravenous (IV) bolus injection. Animals shall be on day 1 and day 8. Respiratory and CV measurements shall be collected simultaneously. Blood samples shall be collected at five (5) prespecified time points on day 8 and shipped to the FDA for bioanalysis. Animal Instrumentation (All Phases)

Tasks:

All animals shall be surgically instrumented with the following:

Vascular access buttons for IV bolus drug administration.
Telemetry implants for continuous cardiovascular data collection.

Respiratory Monitoring (All Phases)

Respiratory data shall be collected using whole body plethysmography (WBP) chambers. Animals shall be acclimated to the WBP apparatus prior to dosing. Data collection shall begin at least 1 hour prior to dosing and continue for up to 5 hours post-dose. The following respiratory parameters shall be measured:

Respiratory frequency
Tidal volume
Minute volume
Peak inspiratory flow
Peak expiratory flow
Inspiratory time
Expiratory time

Cardiovascular Monitoring (All Phases)

Cardiovascular data shall be collected via continuous implanted telemetry. Animals shall be conscious and unrestrained. Data shall be collected from at least 1 hour prior to each dose through approximately 24 hours following each dose (25-hour total duration per dosing occasion). The following CV parameters shall be quantitatively evaluated:

Heart rate
Systolic blood pressure
Diastolic blood pressure
Mean arterial blood pressure
Body temperature

Statistical analysis shall use ANOVA.

Bioanalysis — Blood Sample Collection (All Phases)

Whole blood shall be collected at five (5) prespecified time points on day 8 per animal. Plasma shall be prepared and aliquoted into two (2) aliquots per sample, both shipped to the FDA-specified destination for bioanalysis. Fasting is not required prior to sample collection.

An AAALAC-accredited animal facility with applicable Animal Welfare Assurance and IACUC approval. The study will be conducted under non-GLP conditions.